Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 14/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20227445 | 0.91 | ACE (0.67) | ACELMNA | |
| SCHEMBL19645413 | 0.87 | ACE (0.69) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| SCHEMBL8324111 | 0.85 | ACE (0.58) | ACELMNAABCB11MEN1KMT2A | |
| SCHEMBL31721186 | 0.82 | ACE (0.63) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| SCHEMBL8320933 | 0.81 | MME (0.51) | ACESMN1; SMN2MEN1KMT2A | |
| SCHEMBL14001338 | 0.81 | ACE (0.76) | ACELMNASMN1; SMN2 | |
| SCHEMBL13930194 | 0.79 | ACE (0.52) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| SCHEMBL20224665 | 0.79 | ACE (0.45) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| SCHEMBL14523349 | 0.78 | ACE (0.66) | ACELMNA | |
| SCHEMBL8319633 | 0.78 | ACE (0.68) | ACELMNAABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150098993-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES | CELLWORKS GROUP, INC. | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150098993-A1 | COMPOSITIONS, PROCESS OF PREPARATION OF SAID COMPOSITIONS AND METHOD OF TREATING INFLAMMATORY DISEASES | TNF, C5, IL5 | ACE 798/4885LMNA 869/4885SMN1; SMN2 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.